Biogen shares leap as Alzheimer's drug shows potential to slow disease

Biogen gained billions of dollars in market value on Friday after posting promising results from a trial of one of its experimental Alzheimer ’s disease drugs, marking a rare dose of good news in the daunting field. Cambridge-based Biogen (Nasdaq: BIIB) and its partner, Japanese pharmaceutical company Eisai Co., said late Thursday that patients who received the drug saw a reduction in amyloid — a protein whose buildup in the brain ha s been linked to cognitive decline — after 18 months of treatment,…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news